Sagimet Biosciences (SGMT) Stock
Small biopharmaceutical company developing new medical treatments. Here's the price, business snapshot, and what's worth knowing about Sagimet Biosciences in October 2026.
Sagimet Biosciences Inc. (SGMT) is a small‑cap biopharmaceutical company with a market capitalisation of about $323.22 million. The company is focused on developing novel therapies in the pharmaceutical/biotech space; as a clinical‑stage enterprise its prospects typically hinge on research progress, trial results, regulatory reviews and potential partnerships. For investors this means a profile with higher scientific and execution risk than established, revenue‑generating firms — outcomes from a single study or regulatory decision can materially change the share price. Key considerations include the company’s cash runway, upcoming clinical or regulatory milestones, intellectual property position and any collaboration agreements. Liquidity can be limited in smaller stocks and volatility is common. This summary is for educational purposes only and not personal advice; values can rise or fall and past performance does not guarantee future returns. Consider your risk tolerance and consult a qualified financial adviser before making investment decisions.
Sagimet Biosciences (SGMT) Stock Forecast
Analyst price target, next 12 months
$28.83
+215.5% vs today's $9.14
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Sagimet Biosciences have a consensus 12-month target of $28.83, above the current price of $9.14.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Sagimet's stock with a target price of $28.83, indicating strong growth potential.
Financial Health
SAGIMET BIOSCIENCES INC is showing strong financial performance with solid cash flow and value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Trial readouts and regulatory milestones can move the stock materially — pay attention to timelines and the binary nature of such events, though outcomes are uncertain.
Innovation focus
The company’s value is driven by its science and intellectual property; breakthroughs can create opportunities, but scientific and execution risks remain.
Small‑cap dynamics
Smaller market capitalisation can mean higher growth potential and higher volatility; consider liquidity, diversification and your risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
